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Abstract The CD95/Fas/Apo-1 ligand (CD95L, CD178) in-
duces apoptosis through the death receptor CD95. CD95L was
also described as a co-stimulatory receptor for T-cell activation
in mice in vivo. The molecular basis for the bidirectional
signaling capacity and directed expression of CD95L is
unknown. In the present study we identify proteins that
precipitate from T-cell lysates with constructs containing
fragments of the CD95L cytosolic tail. The determined peptide
mass fingerprints correspond to Grb2, actin, L-tubulin, formin
binding protein 17 (FBP17) and PACSIN2. Grb2 had been
identified as a putative mediator of T-cell receptor-to-CD95L
signaling before. FBP17 and PACSIN2 may be associated with
expression and trafficking of CD95L. When overexpressed,
CD95L co-precipitates with FBP17 and PACSIN. Protein^
protein interactions are mediated via Src homology 3 (SH3)
domain binding to the polyproline region of CD95L and can be
abolished by mutation or deletion of the respective SH3
domain. 4 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
CD95 ligand (CD95L, Apo-1L, FasL, CD178) is a 40 kDa
type II transmembrane receptor of the tumor necrosis factor
(TNF) family of death factors [1]. Its function is best docu-
mented in the context of activation-induced cell death (AICD)
in the T-cell compartment where it plays a pivotal role in the
regulation of thymic or peripheral selection and tolerance and
immune response termination [2^7]. In addition, cytotoxic ac-
tivity of T-cells and NK cells is associated at least in part with
the release of CD95L as an integral component of Golgi-de-
rived secretory lysosomes to act as an e¡ector molecule on
CD95-positive target cells [8^10].
Several reports employing CD95L- and CD95-defective
mouse strains indicated that membrane-bound CD95L might
also act as a co-stimulatory molecule for T-cells. It appears
that ligation of CD95L interferes with TCR signaling and
coordinates cell cycle progression of T lymphocytes. Interest-
ingly, CD95L ligation seems to a¡ect CD4þ and CD8þ T-cell
responses di¡erently. While CD4 cells are inhibited in cell
cycle progression and enter apoptosis, CD8 cells need the
CD95L co-stimulus to progress through the cell cycle, to pro-
liferate and acquire cytolytic e¡ector function [11^12].
Several other members of the TNF family have been as-
signed ‘bidirectional functions’ as co-stimulatory receptors
and as death factors for di¡erent cell types [13^24]. Yet, the
available information concerning the molecules involved in
reverse signal transduction is limited. Six members of the
TNF family (CD27L, CD30L, CD40, CD137L, TNFK,
CD95L) have a putative casein kinase I (CKI) motif
(^SXXS^). Only for TNFK but not for CD95L, a role of
CKI phosphorylation in reverse signal transduction has been
demonstrated [25].
Increasing evidence suggests that the basis for CD95L sig-
naling and function is located within the cytosolic polyproline
stretch which forms an ideal docking region for proline-inter-
acting Src homology 3 (SH3) or WW domains (Fig. 1). Pep-
tides corresponding to the proline-rich region of the murine
CD95L were reported to interact with the SH3 domain of the
Src kinase p59fynðTÞ and it was suggested that CD95L mem-
brane expression is primarily regulated through an association
with the kinase [26]. Our recent studies indicate that in addi-
tion to Fyn, CD95L reverse signaling might involve other
molecules of the Src family, Grb2-related adapter proteins,
PI-3 kinase, Nck, p47phox and also WW domain proteins
such as FE65 or formin binding protein 11 (FBP11) [27].
Moreover, deletion of the proline-rich region of CD95L com-
pletely alters the subcellular localization of the molecule [8].
To search for unknown interactors of CD95L that might
help to understand the regulation of transport and function,
we expressed the cytoplasmic portion of CD95L and used this
to precipitate binding partners. As a result, actin, L-tubulin,
Grb2, FBP17 and PACSIN2 were identi¢ed. With a focus on
the latter three proteins, we demonstrate that CD95L binding
is mediated by SH3 domains in all cases. This was con¢rmed
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in pull-down assays using point mutations of PACSIN2
and in co-precipitation studies with SH3 domain-lacking
FBP17.
2. Materials and methods
2.1. Cells
The human T-cell lines HUT78 and Jurkat E6.1 and the stable
CD95L transfectants KFL-9 [28] were propagated in RPMI 1640
with 5% (v/v) fetal bovine serum and antibiotics at 37‡C in a humidi-
¢ed atmosphere with 5% CO2. T-cell blasts were established from
Ficoll-separated human mononuclear cells by stimulation with phyto-
hemagglutinin A (PHA) as described in [27]. Around day 14, the cells
were stimulated with phorbolester and ionomycin for 5 h to express
CD95L.
2.2. Fusion proteins
The full length CD95L cytosolic region (CD95Lcyto, 80 aa), the
N-terminal part with low proline content (CD95Lcyto1, 29 aa) and
the membrane-proximal portion (CD95Lcyto2, 53 aa) were expressed
as glutathione S-transferase (GST) fusion proteins (Fig. 1). Similarly,
GST fusion proteins containing SH3 domains of human PACSIN2
(aa 429^486, identical to aa 388^445 of the hypothetical protein
gi:12053195, accession AL136845.1), FBP17 (aa 615^672, identical
to aa 524^581 of the ’unnamed protein’; gi:10435680, accession
AK023681.1) and Grb2 (full length, N-terminal SH3 domain corre-
sponding to aa 3^57 and C-terminal SH3 domain corresponding to aa
157^213) were generated. In addition, GST fusion proteins containing
full length murine PACSIN3 and full length and SH3 mutated murine
(P478L) PACSIN2 were used. Of note, the SH3 regions including the
critical proline at position 478 of PACSIN2 are highly conserved
between mouse and man.
2.3. Precipitation and Western blotting
For immunoprecipitation or precipitation with fusion proteins, cells
were lysed in Triton X-100 or Nonidet P-40 (NP40) bu¡ers as de-
scribed [27]. Supernatants were incubated for at least 90 min rotating
at 4‡C with antibody and protein A (i.e. anti-CD95L mAb clones
G-247.4 or NOK1 from PharMingen, anti-myc from Cell Signaling
Technology) or GST fusion protein and glutathione sepharose beads
(Amersham/Pharmacia Biotech). Then, the beads were pelleted,
washed, boiled in sample bu¡er and the precipitated proteins electro-
phoresed on SDS^polyacrylamide gels. Whole cell lysates were run
with 50 Wg/lane. Separated proteins were transferred to nitrocellulose
membranes and blots developed with anti-CD95L (PharMingen), anti-
Grb2 (Santa Cruz Biotechnology) or anti-myc (Invitrogen) and ECL
detection reagents.
2.4. Two-dimensional (2D) gel electrophoresis and peptide mass
¢ngerprinting by matrix-assisted laser desorption ionization
mass spectrometry (MALDI-MS)
For 2D separation of CD95L-associated proteins, 109 HUT78 cells
were lysed in 10 ml of NP40 lysis bu¡er. The lysate was precleared for
90 min with GST and glutathione beads. The supernatant was then
split in three aliquots and incubated with the individual CD95Lcyto
fusion proteins and glutathione beads for another 90 min. The beads
were then washed, dried by aspiration and dissolved for 30 min at
50‡C in 50 Wl of sample bu¡er with urea, NP40, 2L-mercaptoethanol
and carrier ampholytes. Then, 210 Wl of rehydration bu¡er were
Fig. 1. A: CD95L is a member of the TNF superfamily of transmembrane type II death factors and consists of 281 aa with a cytoplasmic tail
of 80 aa, a transmembrane section of 22 aa and a glycosylated (three sites indicated) extracellular part of 179 aa. The intracellular portion con-
tains a CKI motif (aa 17^21) and a unique proline-rich stretch. B: The following GST fusion proteins were used to identify CD95L binding
proteins: GST^CD95Lcyto contains the complete cytoplasmic tail, GST^CD95Lcyto1 the N-terminal region and GST^CD95Lcyto2 the proline-
rich part of the molecule. All puri¢ed proteins were routinely analyzed by protein staining.
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added and incubation was prolonged for 30 min. Supernatants were
recovered and transferred on Immobiline DryStrips (pH 3^10 L) and
focused on IPGphor equipment (Amersham/Pharmacia Biotech) with
standard conditions. After isoelectric focusing, the strips were equili-
brated and the second dimension was carried out by standard SDS^
PAGE on 11% gels. The gels were stained with Coomassie brilliant
blue R 250. Single gel spots were punched out for in-gel digestion with
trypsin (Promega) for 16 h. The samples were dissolved in aqueous
TFA/acetonitrile (2:1) for mass spectrometrical analysis. The mass
spectra were recorded by using a time-of-£ight delayed extraction
MALDI mass spectrometer (Voyager-Elite, Perseptive Biosystems).
50 mg/ml 2,5-dihydroxybenzoic acid in 0.3% aqueous TFA/acetoni-
trile (2:1) was used as matrix. The spectra were obtained in the re-
£ectron mode by summing 70^200 laser shots. Proteins were identi¢ed
by using the peptide mass ¢ngerprinting analysis software ProFound
(http://canada.proteometrics.com/prowl-cgi/ProFound.exe?-
FORM=1). The NCBI database with the species human was used for
the searches by considering at maximum one missed cleavage site,
oxidation of methionine, acetylation of the N-terminus, modi¢cation
of cysteines by acrylamide and a mass accuracy of 100 ppm for mono-
isotopic masses.
2.5. Transfection
Human 293T cells were maintained in DMEM with 10% (v/v) FBS.
6U105 cells were seeded in 10 cm dishes 1 day before transfection
with 5 Wg of DNA using the calcium-phosphate method. Transiently
transfected cells were analyzed after 24 h. As expression vectors, we
used full length FBP17, FBP17(3SH3) (lacking the SH3 domain) in
pcDNA3.1D/V5-His (Invitrogen), PACSIN2 in pMyc-CMV (Clon-
tech) or the closely related PACSIN1 with a myc-tag in pcDNA3.
The pcDNA3-based CD95L expression plasmid PL217s was kindly
provided by Pascal Schneider and Margot Thome¤ from Lausanne.
3. Results
3.1. Identi¢cation of CD95L interacting proteins by
2D-electrophoresis
CD95L fusion proteins were used in pull-down experiments
to search for interacting proteins in lysates from HUT78 leu-
kemic cells (Fig. 2). GST was used to preclear the lysates from
GST-associating material (Fig. 2A). GST^CD95Lcyto1 con-
taining only a few proline residues precipitated very low
amounts of proteins (Fig. 2B). In contrast, the GST^
CD95Lcyto2 fusion protein with the proline-rich fragment
(Fig. 2D) and the GST^CD95Lcyto fusion protein containing
the complete cytosolic tail (Fig. 2C) precipitated an overlap-
ping set of proteins visualized by Coomassie staining and
suitable for analysis by MALDI time-of-£ight MS. Using
high stringency criteria, seven out of eight spots detected in
GST^CD95Lcyto precipitates and three out of three spots
from GST^CD95Lcyto2 precipitates were identi¢ed (Fig.
2C^E). The peptide masses of the proteins excised from
GST^CD95Lcyto2 precipitates were identical to the respective
spots in GST^CD95Lcyto precipitates and corresponded to
an unknown protein of 72 kDa (accession AK023681.1) and
Fig. 2. GST^CD95L fusion proteins were used for precipitation from HUT78 cells. Precipitated material was separated by 2D gel electrophore-
sis with isoelectric focusing (pH 3^10) in the ¢rst and SDS^PAGE in the second dimension. A: GST served as a control to visualize back-
ground staining with Coomassie blue. B: Precipitation with (GST^CD95Lcyto1) did not yield any excisable spots above background. C: With
GST^CD95Lcyto, a large number of additional spots were detected by Coomassie staining. D: GST^CD95Lcyto2 delivered an overlapping pat-
tern of binding proteins. Three spots that were further analyzed corresponded to respective spots in (C). E: Eight spots of (C) were subjected
to tryptic digestion and peptide mass ¢ngerprint. Spots 1 and 2 yielded identical peptide mass ¢ngerprints and were identi¢ed as an unnamed
protein of 72 kDa (up72, AK023681.1), spot 3 as actin, spot 4 as a hypothetical protein of 53 kDa (hp53, AL136845.1), spot 5 as L-tubulin,
spot 6 as GST and spot 8 as Grb2.
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a hypothetical protein of 53 kDa (AL136845.1), respectively.
In addition, from GST^CD95Lcyto pull-downs, actin and
L-tubulin were identi¢ed as well as GST and the adapter pro-
tein Grb2. Homology searches with the sequences of the ‘un-
known protein of 72 kDa’ and the ‘hypothetical protein of
53 kDa’ yielded that these proteins might in fact be identical
to the FBP17 and PACSIN2, respectively.
3.2. Western Blot detection of Grb-2 associated with
CD95L fragments
We recently suggested that Grb2 and other members of the
Grb2/Gads/Grap family of adapter proteins might interact
with CD95L [27] and thereby provide the link to TCR signal-
ing. In Western blotting experiments, we were able to visualize
(co-)precipitated Grb2 using our CD95L constructs for pre-
cipitation from di¡erent T-cell lines such as Jurkat or HUT78
(Fig. 3A). However, using di¡erent anti-Grb2 antibodies to
co-immunoprecipitate CD95L from stable transfectants
(KFL-9), we obtained inconsistent results. Only a single batch
of a polyclonal antiserum co-precipitated CD95L as a doublet
typical for these cells whereas all other anti-Grb2 antibodies
or antisera failed to do so (Fig. 3B).
3.3. Association of Grb2, FBP17 and PACSIN2 with
CD95L depends on SH3 binding
From our previous studies we knew that a number of SH3
domains strongly bind to the proline-rich region of CD95L
[27]. Thus, we focused on the three candidate binding partners
that contain SH3 regions (Fig. 4A). We expressed full length
Grb2 and both SH3 domains separately as GST fusion pro-
teins and analyzed whether the puri¢ed fusion proteins were
capable of binding to overexpressed CD95L. Clearly, the full
length Grb2 fusion protein and the C-terminal SH3 domain
strongly associated with CD95L in vitro (Fig. 4B). Similar
results were obtained with PHA blasts where we also detected
some binding to the N-terminal SH3 domain but the strongest
interaction with the complete molecule (not shown).
FBP17 and PACSIN2 belong to a family of structurally
related proteins that have been associated with lysosomal
transport processes and signal transduction. Both proteins
share an overall composition with an N-terminal FCH (Fes/
Fer/CIP4 homology) domain, a central coiled-coil region and
a C-terminal SH3 domain. Clearly, only fragments containing
the respective SH3 domains were able to precipitate signi¢cant
amounts of CD95L from KFL-9 cells (Fig. 4C) or T-cell
blasts (not shown). We also generated GST fusion proteins
containing SH3 domains of other members of this protein
family and employed their capability to interact with
CD95L. In vitro pull-down assays revealed that the SH3 do-
mains of most proteins of this family precipitate CD95L from
transfectants and T-cell blasts. Tested proteins include the
closely related PACSIN1 and PACSIN3, the CD2 binding
protein 1 (CD2Bp1, SH3 domain identical to the one of the
PEST phosphatase interacting protein homolog), the Rho-
Fig. 3. A: The association of Grb2 with the proline-rich portion of CD95L was veri¢ed by Western blot analysis. GST^CD95Lcyto and GST^
CD95Lcyto2 constructs precipitated Grb2 from lysates of Jurkat and HUT78 cells (see arrow). B: Failure to co-precipitate CD95L with Grb2
from CD95L transfectants. Having learned during the previous analyses of CD95L-interacting SH3 proteins that a certain batch of Grb2 anti-
body (polyclonal anti-Grb2 (rabbit) from Santa Cruz SC255-lot F219) in fact might co-precipitate CD95L, we used a number of other anti-
Grb2 antibodies to con¢rm this result. Obviously, none of the other batches of this antibody nor any of the other tested antibodies was able
to co-precipitate CD95L from KFL-9 transfectants. The CD95L doublet precipitated with mAb NOK-1 from KFL9 cells served as a positive
control.
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GAP C1 and the RhoGAP C1-related protein with compara-
ble domain structure KIAA0456, the FLJ00007 protein and
the CDC42-interacting protein CIP4 (O15184) (data not
shown). The speci¢city of SH3-mediated CD95L interactions
with full length Grb2 and the SH3 domains of PACSIN2 and
FBP17 was demonstrated in titration experiments with KFL-9
lysates (Fig. 5B).
Having shown that the SH3 domain of PACSIN2 interacts
with CD95L, we were next interested to analyze whether a
single amino acid exchange mutation within the SH3 domain
(P478L) would result in an abrogation of binding. To this
end, PACSIN2 fusion proteins were used to precipitate
CD95L from stimulated PHA blasts. As shown in Fig. 6,
full length (murine) PACSIN2 and PACSIN3 were as e⁄cient
in such pull-down experiments as isolated (human) SH3 do-
mains. Importantly, the single point mutation (P478L) within
the PACSIN2 SH3 domain completely abrogated CD95L
binding (Fig. 6).
3.4. CD95L co-precipitates with FBP17 and PACSIN2
FBP17, FBP173SH3 and PACSIN2 or PACSIN1 were
transiently transfected with or without CD95L in 293 T-cells.
NP40 lysates of single or co-transfectants were used to pre-
cipitate CD95L with anti-CD95L mAb or the putative inter-
actors with anti-myc mAb. Protein expression was analyzed in
whole cell lysate with anti-CD95L or anti-myc mAb, respec-
tively. Single and double transfection was successful in all
cases although the amount of protein expressed varied to
some extend (upper panel of Fig. 7A). Importantly, anti-
myc immunoprecipitation followed by CD95L staining of
the Western blot revealed co-precipitated CD95L only in cases
where the expressed proteins contained SH3 domains but not
when the FBP17 construct without SH3 domain was co-trans-
fected. Interestingly, when CD95L was precipitated from dou-
ble transfectants, only PACSIN2 but not FBP17 or PACSIN1
was detected as co-precipitated myc-tagged material (Fig. 7B).
4. Discussion
Recent studies with mutant mice indicate that CD95L
serves not only as a death factor and ligand for CD95 but
also as a co-stimulatory receptor and modulator of T-cell
activation in vivo. For CD4-positive cells, CD95L engagement
was reported to inhibit TCR-driven cell cycle progression,
Fig. 4. A: Data bank searches revealed that the unnamed protein up72 corresponds to the FBP17 and hp53 to PACSIN2. The overall domain
composition of these molecules and of Grb2 is shown. B,C: We expressed di¡erent parts of FBP17, PACSIN2 and Grb2 as fusion proteins to
determine the individual CD95L-interacting domain. As expected, only the SH3 domains were able to precipitate CD95L from KFL-9 cells. In
the case of Grb2, the full length fusion protein (protein staining and anti-CD95L probing are shown) and the C-terminal SH3 domain precipi-
tated substantial amounts of CD95L (B). Also for FBP17 and PACSIN2, the isolated SH3 domains expressed as GST fusion proteins showed
strong binding of CD95L in pull-down experiments (C).
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associated with increased rates of apoptosis [11,12,29]. Inter-
estingly, a population-speci¢c bias of CD95L action was sug-
gested by several reports showing that under similar condi-
tions, CD8-positive cells enter the cell cycle and proliferate
when CD95L is engaged together with the TCR [12,29,30].
The molecular basis for the reverse signaling of CD95L re-
mained unclear.
Biochemically most relevant, the membrane-proximal por-
tion of the cytoplasmic tail of CD95L contains a polyproline
stretch that is likely to allow binding of proline-reactive SH3
Fig. 6. GST^PACSIN fusion proteins were used to precipitate CD95L from lysates from human PHA blasts stimulated with PMA and ionomy-
cin for 5 h. For each precipitation, 90U106 T-cell blasts were lysed in 1 ml lysis bu¡er. Precipitates with anti-CD95L mAb of the same lysate
served as a positive and with GST as a negative control. Ponceau S staining (A) and anti-CD95L staining (B). Clearly, a single point mutation
(P478L) within the PACSIN2 SH3 domain abrogates the CD95L-interaction.
Fig. 5. The speci¢city of interaction with full length Grb2 and the previously identi¢ed CD95L interacting N-terminal SH3 domain phox47 (A)
as well as the SH3 domains of FBP17 and PACSIN2 (B) were tested. Titration of the fusion proteins (50^0.5 Wg) is nicely seen by the parallel
titration of precipitated CD95L from 5U106 KFL-9 cells. Precipitates with anti-CD95L mAb NOK-1 of the same lysate served as a control
and as an indication for ’CD95-loading’ of the transfectants. Fusion proteins were visualized by Ponceau S-staining and CD95L was detected
with mAb G247-4.
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or WW domains [31,32]. In 1995, binding of the SH3 domain
of the Src kinase p59fynðTÞ to CD95L-derived peptides was
reported [26]. In 1996, Hachiya deposited several protein frag-
ments in the NCBI database that they found to interact with
CD95L in a yeast two-hybrid screen. All these Fas-ligand
associated factors (FLAF1^3) contained either WW or SH3
domains. Although no further results were published it is now
clear that the FLAFs correspond to FBP11, the c-Cbl-associ-
ated protein, and the BAI1-associated protein 2L, respectively.
Recently, we showed that a number of other SH3 or WW
modules are also capable of interacting with full length
CD95L [27]. Among these, Src kinases, Grb2-related adapter
proteins, PI-3 kinase, Nck, p47phox, FE65 or FBP11 mediate
critical steps in activation associated with antigen receptor,
adhesion molecule or co-stimulatory downstream signaling.
In the present report, we identify proteins that interact with
the proline-rich cytoplasmic portion of CD95L. Our results
provide further evidence for the reverse signaling capacity of
CD95L and strongly suggest that the expression and transport
of CD95L seems to be regulated in a coordinated and com-
plex fashion via the proline-rich region of the molecule. Im-
portantly, we con¢rmed our previous result showing that
Grb2 precipitates with proline-containing CD95L constructs.
Grb2 is a well-de¢ned adapter protein that plays a pivotal role
in growth factor receptor as well as TCR signaling. After
TCR-activation the Grb2^Sos complex is recruited to the
phosphorylated transmembrane adapter, linker for activated
T-cells (LAT), thereby triggering the Ras/MAPK pathway
and leading to transcription of a whole range of proteins
needed for T-cell activation and di¡erentiation [33]. An inter-
action of Grb2 and CD95L could thus point to a crosstalk
between CD95L and the TCR.
PACSIN2 is a cytosolic adapter protein that links clathrin-
dependent endocytosis to the actin cytoskeleton and is in-
volved in the regulation of vesicular tra⁄c [34^38]. All PAC-
SINs contain phosphorylation sites for CKII and protein ki-
nase C (the name PACSIN refers to ‘protein kinase C and
CK2 substrate in neurons’). Moreover, it was reported that
PACSIN isoforms speci¢cally interact with Sos, thereby reg-
ulating actin dynamics via MAPK signaling [38]. In the con-
text of CD95L, PACSIN2 could be involved in the reorgan-
ization of the cytoskeleton and in tra⁄cking of cytoplasmic
vesicles leading to compartimentalization and regulation of
extrusion of CD95L.
FBP17 belongs to the heterogeneous group of FBPs. In
association with the various formins, these proteins regulate
the organization and assembly of the actin cytoskeleton and
are involved in orchestrating cell motility, adhesion and cyto-
kinesis [39]. FBP17 contains a C-terminal SH3-domain that
interacts with CD95L. FBP17 is widely expressed in a variety
Fig. 7. FBP17, FBP17-SH3, PACSIN1 and PACSIN2 were transiently transfected in 293 T-cells as myc-tagged fusion proteins alone or co-
transfected with CD95L by the calcium phosphate method. NP40 lysates were made 24 h after transfection. The expression of each protein was
analyzed in 50 Wg of whole cell lysate, e.g. with anti-CD95L mAb (A, upper panel). The lysates were split into two aliquots for parallel immu-
noprecipitation (IP) with anti-CD95L or anti-myc mAb as indicated. Proteins were transferred to nitrocellulose and analyzed with anti-CD95L
and anti-myc antibodies. A: Anti-myc immunoprecipitation followed by CD95L staining revealed co-precipitated CD95L in the presence of in-
tact SH3 domains. B: When CD95L mAb was used to precipitate from double transfectants, only the myc-tagged PACSIN2 was stained
although the amount of CD95L was clearly lower in these cells.
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of human tissues [40]. FBP17 interacts with sorting nexin 2
(SNX2) and thus provided a link between MLL, a gene con-
nected to myelogenous leukemia, and the epidermal growth
factor receptor (EGFR) pathway. In general, SNX proteins
are also involved in protein tra⁄cking and lysosomal target-
ing. Therefore, association of CD95L with FBP17 could once
again indicate a mode of action of lysosomal transport of
CD95L and also point to a signaling crosstalk between the
death factor and the EGFR pathway.
We also found actin and L-tubulin in CD95Lcyto precipi-
tates. This could be more evidence for the association of
CD95L with lysosomes and/or cytoskeletal elements. Thus,
L-tubulin is a major component of microtubules, arranging
the mitotic spindle during cell division and regulating axonal
transport and organelle positioning [41]. In addition, it was
reported that tubulin plays an important role in G-protein-
mediated signal transduction [42]. Obviously, even though tu-
bulins are structural proteins, they participate in cellular sig-
naling albeit through physical forces. In this scenario, it is
discussed whether tubulins modulate the conformation of re-
ceptors or G-proteins leading either to a change in receptor^
ligand interaction and/or in£uencing the G-protein-mediated
signal.
An interesting phenomenon associated with CD95L upon
TCR-activation in the course of AICD and during cytotox-
icity mediated by cytolytic T-cells is that CD95L surface ex-
pression as seen on CD4-positive T-cells [43,44,29] and lyso-
somal expression and transport associated with cytotoxic
(CD4þ or CD8þ) T-cells and NK cells [8^10,45,46] may be
regulated di¡erentially and thus require distinct sets of
CD95L binding proteins. In both cases, the association with
regulatory elements seems to depend, however, on the proline-
rich region of the cytosolic portion of the molecule [8]. It has
been suggested that the sorting of the CD95L from the Golgi
to the secretory lysosome may provide a general mechanism
for controlling the cell surface appearance of proteins in-
volved in immune regulation. In that sense, the ¢nding that
all tested SH3 domains of proteins characterized by FCH and
SH3 domains are capable of interacting with CD95L suggests
that this protein family plays a key role in directed transport
in cells.
The association of membrane-associated or intracellular
CD95L with a multitude of adapter proteins or enzymes
may therefore not only explain the crosstalk between a death
factor and antigen receptors or growth factor receptors. The
present observations may also help to ¢nally identify the bio-
chemical basis for the functional sorting of CD95L during
expression either on cell surfaces or in secretory lysosomes.
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